Clinical trial · Interventional
Bevacizumab and Combination Chemotherapy as First-Line Therapy in Treating Patients With Metastatic Colorectal Cancer That Cannot Be Removed By Surgery
Phase II Randomized Study of First-Line Therapy Comprising Bevacizumab and Irinotecan Hydrochloride, Leucovorin Calcium, and Fluorouracil (FOLFIRI) Versus Bevacizumab and Irinotecan Hydrochloride and Capecitabine (XELIRI) in Patients With Unresectable Metastatic Colorectal Cancer [ACCORD]
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Bevacizumab may also stop the growth of colorectal cancer by blocking blood flow to the tumor. Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving bevacizumab together with combination chemotherapy may kill more tumor cells. It is not yet known which combination chemotherapy regimen is more effective when given together with bevacizumab in treating patients with colorectal cancer. PURPOSE: This randomized phase II trial is studying bevacizumab to compare how well it works when given together with two different combination chemotherapy regimens as first-line therapy in treating patients with metastatic colorectal cancer that cannot be removed by surgery.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Colorectal Cancer | Malignant Colorectal Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (5)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| bevacizumab | Biological | Bevacizumab | ALIAS |
| capecitabine | Drug | Capecitabine | ALIAS |
| fluorouracil | Drug | Fluorouracil | ALIAS |
| irinotecan hydrochloride | Drug | Irinotecan | ALIAS |
| leucovorin calcium | Drug | Leucovorin | ALIAS |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- bevacizumab + FOLFIRI
- interventionNames
- Biological: bevacizumab
- Drug: fluorouracil
- Drug: irinotecan hydrochloride
- Drug: leucovorin calcium
- type
- EXPERIMENTAL
- label
- bevacizumab + XELIRI
- interventionNames
- Biological: bevacizumab
- Drug: capecitabine
- Drug: irinotecan hydrochloride
Primary outcomes (1)
- measure
- Progression-free survival at 6 months
Secondary outcomes (7)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
DISEASE CHARACTERISTICS: * Histologically confirmed colorectal cancer * Unresectable metastatic disease * Measurable disease * No CNS metastases PATIENT CHARACTERISTICS: * WHO performance status 0-2 * Life expectancy \> 3 months * Absolute neutrophil count \> 1,500/mm³ * Platelet count \> 100,000/mm³ * Hemoglobin \> 9 g/dL (transfusion allowed) * INR \< 1.5 * Alkaline phosphatase \< 1.5 times upper limit of normal (ULN) * Bilirubin \< 1.5 times ULN * AST and ALT \< 2.5 times ULN (5 times ULN if liver metastases are present) * Creatinine clearance \> 30 mL/min * Urine protein \< 2+ OR ≤ 1 g/L by 24-hour urine collection * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception * No contraindications to study therapy * No gastrointestinal or duodenal ulcers * No AIDS * No serious illness, active infection, or other serious condition that would preclude study therapy * No coagulation problem * No bleeding diathesis * No sensitivity to Chinese hamster ovarian cells or other recombinant human antibodies * No severe renal insufficiency * No uncontrolled hypertension * No active or severe cardiovascular conditions, including the following: * Cerebrovascular accident * Myocardial infarction within the past 6 months * New York Heart Association class II-IV cardiac insufficiency * Severe cardiac arrhythmia (even if treated) * No primitive stenosis or symptomatic peritoneal carcinosis causing a risk of intestinal subocclusion or occlusion * No nonhealing wound or fracture * No prior thromboembolic disease * No other cancer within the past 2 years except for basal cell skin cancer or carcinoma in situ of the uterine cervix * No geographical, social, or psychological condition that would preclude study participation PRIOR CONCURRENT THERAPY: * No prior chemotherapy for metastatic disease * At least 6 months since prior adjuvant chemotherapy (fluorouracil with or without oxaliplatin) * No prior adjuvant chemotherapy comprising irinotecan hydrochloride with or without bevacizumab * At least 28 days since prior major surgery * Prior radiotherapy allowed except to target lesions * At least 10 days since prior anticoagulants * No concurrent chronic acetylsalicylic acid (at doses \> 325 mg/day) * No other concurrent investigational therapy * No other concurrent anticancer therapy
References
Publications (2)
- RESULTMalka D, Boige V, Jacques N, Vimond N, Adenis A, Boucher E, Pierga JY, Conroy T, Chauffert B, Francois E, Guichard P, Galais MP, Cvitkovic F, Ducreux M, Farace F. Clinical value of circulating endothelial cell levels in metastatic colorectal cancer patients treated with first-line chemotherapy and bevacizumab. Ann Oncol. 2012 Apr;23(4):919-27. doi: 10.1093/annonc/mdr365. Epub 2011 Aug 8. PMID 21825101
- DERIVEDAntoun S, Bayar MA, Dyevre V, Lanoy E, Smolenschi C, Ducreux M. No evidence for changes in skeletal muscle mass or weight during first-line chemotherapy for metastatic colorectal cancer. BMC Cancer. 2019 Aug 28;19(1):847. doi: 10.1186/s12885-019-6086-2. PMID 31462288